中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2012年
11期
1630-1631
,共2页
脑梗死%白细胞介素-6%内皮素%趋化因子类%阿托伐他汀
腦梗死%白細胞介素-6%內皮素%趨化因子類%阿託伐他汀
뇌경사%백세포개소-6%내피소%추화인자류%아탁벌타정
Brain infarction%Interleukin-6%Endothelin%Chemotactic factors%Atorvastatin
目的 探讨阿托伐他汀对急性脑梗死( ACI)患者血清白细胞介素-6(IL-6)、内皮素(ET)和单核细胞趋化因子(MCP-1)水平以及神经功能的影响.方法 将100例ACI患者随机分为阿托伐他汀组(50例)和常规治疗组(50例),阿托伐他汀组在常规治疗基础上加用阿托伐他汀20mg,每天1次,连续服用4周.观察比较治疗前后血清IL-6、ET、MCP-1水平及神经功能缺损程度评分(NDS)评定,并以30例健康体检正常者作为对照组.结果 常规治疗组和阿托伐他汀组血清IL-6、ET及MCP-1水平较对照组明显升高(t=26.38、49.10、34.51、25.77、32.23、34.68,均P＜0.05)；治疗后,阿托伐他汀组较常规治疗组血清IL-6、ET及MCP-1水平下降更明显(t=10.10、13.18、23.85,均P＜0.05)；两组NDS评分较治疗前明显下降(t=18.38、6.98,均P＜0.05),且阿托伐他汀组较常规治疗组下降更明显(t=12.00,P＜0.05).结论 阿托伐他汀能明显降低ACI患者血清IL-6、ET及MCP-1水平,有助于ACI患者的神经功能恢复.
目的 探討阿託伐他汀對急性腦梗死( ACI)患者血清白細胞介素-6(IL-6)、內皮素(ET)和單覈細胞趨化因子(MCP-1)水平以及神經功能的影響.方法 將100例ACI患者隨機分為阿託伐他汀組(50例)和常規治療組(50例),阿託伐他汀組在常規治療基礎上加用阿託伐他汀20mg,每天1次,連續服用4週.觀察比較治療前後血清IL-6、ET、MCP-1水平及神經功能缺損程度評分(NDS)評定,併以30例健康體檢正常者作為對照組.結果 常規治療組和阿託伐他汀組血清IL-6、ET及MCP-1水平較對照組明顯升高(t=26.38、49.10、34.51、25.77、32.23、34.68,均P＜0.05)；治療後,阿託伐他汀組較常規治療組血清IL-6、ET及MCP-1水平下降更明顯(t=10.10、13.18、23.85,均P＜0.05)；兩組NDS評分較治療前明顯下降(t=18.38、6.98,均P＜0.05),且阿託伐他汀組較常規治療組下降更明顯(t=12.00,P＜0.05).結論 阿託伐他汀能明顯降低ACI患者血清IL-6、ET及MCP-1水平,有助于ACI患者的神經功能恢複.
목적 탐토아탁벌타정대급성뇌경사( ACI)환자혈청백세포개소-6(IL-6)、내피소(ET)화단핵세포추화인자(MCP-1)수평이급신경공능적영향.방법 장100례ACI환자수궤분위아탁벌타정조(50례)화상규치료조(50례),아탁벌타정조재상규치료기출상가용아탁벌타정20mg,매천1차,련속복용4주.관찰비교치료전후혈청IL-6、ET、MCP-1수평급신경공능결손정도평분(NDS)평정,병이30례건강체검정상자작위대조조.결과 상규치료조화아탁벌타정조혈청IL-6、ET급MCP-1수평교대조조명현승고(t=26.38、49.10、34.51、25.77、32.23、34.68,균P＜0.05)；치료후,아탁벌타정조교상규치료조혈청IL-6、ET급MCP-1수평하강경명현(t=10.10、13.18、23.85,균P＜0.05)；량조NDS평분교치료전명현하강(t=18.38、6.98,균P＜0.05),차아탁벌타정조교상규치료조하강경명현(t=12.00,P＜0.05).결론 아탁벌타정능명현강저ACI환자혈청IL-6、ET급MCP-1수평,유조우ACI환자적신경공능회복.
Objective To explore the effect ot atorvastatin on the levels of serum Interleukin-6 ( IL-6),Endothelin(ET) and MCP-1 in patients with acute cerebral infarction(ACI).Methods 100 patients with ACI were randomly divided into the atorvastatin therapy group(n =50) and the conventional therapy group(n =50).At the basic of conventional therapy,the atorvastatin therapy group was treated with Atorvastatin 20mg/d.Both groups were treated for 4 weeks.The levels of serum IL-6,ET and MCP-1 were measured and the scores of neurological deficit ( NDS ) were evaluated before and after treatment.A healthy control group which approximately matched the experimental group included 30 persons.Results The levels of serum IL-6,ET and MCP-1 in both two groups after 14d treatment were significantly lower than those before treatment(t =26.38,49.10,34.51,25.77,32.23,34.68,P ＜0.05),and the levels of serum IL-6,ET and MCP-1 in atorvastatin therapy group was significantly lower than that in conventional therapy group( t =10.10,13.18,23.85,P ＜0.05 ).NDS of both groups after treatment was lower than those before treatment(t =18.38,6.98,P ＜0.05 ),and the score of atorvastatin therapy group was significantly lower than that of conventional therapy group( t =12.00,P ＜ 0.05).Conclusion Atorvastatin could significantly decrease the levels of serum IL-6,ET and MCP-1,and it could promote the neurological fuction recovery in the patients with ACI.
